Drugs / Live attenuated influenza virus
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01924208 Comparator | Oct 2013 → Sep 2016 | — | Turku University Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live attenuated influenza virus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01924208 ↗ |
| Known as | Fluenz | “Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).” NCT01924208 ↗ |
| Modality | Vaccine | “nasal live attenuated influenza vaccine” NCT01924208 ↗ |
| Route | Intranasal | “nasal live attenuated influenza vaccine” NCT01924208 ↗ |